Name: | Description: | Size: | Format: | |
---|---|---|---|---|
2.04 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Chitosan (CS) and chondroitin sulfate (CHS) are natural polymers with
demonstrated applicability in drug delivery, while nanoparticles are one of the most explored
carriers for transmucosal delivery of biopharmaceuticals. In this work we have prepared
CS/CHS nanoparticles and associated for the first time the therapeutic protein insulin.
Fluorescein isothiocyanate bovine serum albumin (FITC-BSA) was also used to enable
comparison of behaviors regarding differences in molecular weight (5.7 kDa versus 67 kDa).
Nanoparticles of approximately 200 nm and positive zeta potential around +20 mV were
obtained. These parameters remained stable for up to 1 month at 4 C. Proteins were
associated with efficiencies of more than 50%. The release of FITC-BSA in PBS pH 7.4
was more sustained (50% in 24 h) than that of insulin (85% in 24 h). The biocompatibility
of nanoparticles was tested in Calu-3 and A549 cells by means of three different assays.
The metabolic assay MTT, the determination of lactate dehydrogenase release, and the
quantification of the inflammatory response generated by cell exposure to nanoparticles have
indicated an absence of overt toxicity. Overall, the results suggest good indications on the
application of CS/CHS nanoparticles in respiratory transmucosal protein delivery, but the set
of assays should be widened to clarify obtained results.
Description
Keywords
Biocompatibility Chitosan Chondroitin sulfate Nasal delivery Polyelectrolyte complexes Polysaccharides Protein delivery Pulmonary delivery
Citation
Materials 2015, 8, 5647-5670
Publisher
MDPI